INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845P958. A total of 5 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $1,346,000 | -55.7% | 281 | -41.7% | 0.09% | -63.5% |
| Q1 2020 | $3,035,000 | -80.0% | 482 | -60.6% | 0.25% | -80.9% |
| Q4 2019 | $15,143,000 | +265.1% | 1,222 | +95.5% | 1.32% | +246.6% |
| Q3 2019 | $4,148,000 | -25.2% | 625 | +26.0% | 0.38% | -29.4% |
| Q1 2019 | $5,548,000 | – | 496 | – | 0.54% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Caligan Partners LP | 1,200,000 | $22,248,000 | 10.22% |
| GROUP ONE TRADING, L.P. | 24,800 | $459,792 | 0.00% |
| SIMPLEX TRADING, LLC | 53,200 | $986 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| JANE STREET GROUP, LLC | 68,500 | $1,269,990 | 0.00% |